logo-loader

MGC Pharmaceuticals appoints highly experienced sales director to implement global growth strategy

Published: 20:18 12 Jan 2021 EST

MGC Pharmaceuticals Ltd -
MGC is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines

MGC Pharmaceuticals Ltd (ASX:MXC) (OTCMKT:MGCLF) has appointed highly experienced sales director Nicole Godresse as its new global chief sales officer, effective immediately.

Godresse will lead the company’s global sales and marketing initiatives across Australia and New Zealand as well as build and implement a strong and focused pharma sales strategy by recruiting a highly experienced sales force around the world.

The new strategy will be rolled out following the completion of the integration of the recently acquired Medicinal Cannabis Clinics and the board is confident it will deliver strong commercial results taking the company through to its next phase of growth, as an Australian market leader.

Godresse has more than 20 years’ experience in the pharmaceutical and healthcare industry, holding senior commercial roles with major multi-national companies including Eli Lilly, Johnson & Johnson, Schering-Plough, Merck Sharp & Dohme and most recently Tilray.

"New and refocused growth strategy"

Co-founder and MD Roby Zomer said: “We are delighted to welcome Nicole to the team and are extremely impressed with her experience and expertise.

“MGC Pharma delivered significant commercial progress during 2020 and we are focused on ensuring this trajectory continues with a new and refocused accelerated growth strategy.”

MGC Pharmaceuticals reveals strategic objectives for H1 2024

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) CEO and Managing Director Roby Zomer speaks to Thomas Warner from Proactive London following the completion of a share consolidation and capital raise. With these restructuring initiatives completed, Zomer shares his enthusiasm for the...

on 11/13/2023